Singapore, June 12 -- Japan's Lotte Holdings has announced an investment in ClearideBio Therapeutics AG, an early-stage biotechnology startup pioneering next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumours.

Founded in December 2025 and headquartered in Basel, Switzerland, ClearideBio is a preclinical-stage company building a rapidly expanding pipeline of ADC programmes designed to address critically unmet medical needs in oncology.

ClearideBio is currently advancing its lead preclinical ADC programme toward initial clinical development, while continuing to expand its broader pipeline of next-generation ADC assets targeting multiple solid tumour indications. The company's near-term development strategy is fo...